

21st WCIRD

World Congress Insulin Resistance
DIABETES & CARDIOVASCULAR DISEASE

EARN
26.75
CME
ABIM-MOC
CREDITS

December 7–9, 2023
Hilton Universal City Hotel
Los Angeles, CA



Administered by Metabolic Institute of America

Exploring New Frontiers In Metabolism – Tomorrow's Clinical Science Today

JOINTLY PROVIDED



ADMINISTERED BY:



www.WCIR.org



@wcirdc

#WCIRD2023





Welcome.

It is my pleasure to welcome you to the 21st Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC): Exploring New Frontiers in Metabolism—Tomorrow's Clinical Science Today. The 21st Annual WCIRDC will be held on December 7–9, 2023, at the Hilton Universal City, Los Angeles. This CME/MOC conference will be available On-Demand for 90 days following the meeting.

Since its inception, the congress has become the premier global meeting dedicated to metabolism- obesity, diabetes, lipids, HTN, CKD, CVD, HF, and NAFLD. This is the only conference of its size that incorporates clinical, translational and basic science. It offers an exclusive platform allowing professionals, clinicians and researchers to exchange ideas and collaborate on emerging scientific and management concepts.

The WCIRDC faculty consists of globally acclaimed experts who link research to clinical practice in a bench-to bedside-to-bench approach which is unique to this state-of-the-art program.

We are proud to honor Professor Paul Zimmet, AO, MBBS, MD, PhD with the prestigious "Gerald Reaven Distinguished Leader in Insulin Resistance Award", recognizing his exceptional contributions to the field. Dr Zimmet's keynote lecture: Insulin Resistance and its outcomes in T2DM: A Historical and Epidemiological Perspective.

This year's conference will cover a wide range of topics including Lipidology, Cardiomyopathy & Heart Failure, Contemporary Management Of Obesity And Diabetes, The Multiple Faces Of Insulin Resistance, Women's Health State Of The Art Approach To Kidney, and Heart Disease, a joint session with the journal Metabolism; and much more encompassing the multifaceted realm of metabolic medicine. Distinguished experts are poised to unveil groundbreaking perspectives fostering an environment conducive to collaborative learning and professional growth.

Clinical workshops & meet-the-expert small groups sessions will provide attendees with a rare opportunity to personally interact with esteemed leaders in an intimate setting.

The Congress has a strong and highly successful abstracts program. Abstracts will be published in Metabolism Clinical and Experimental- IF 13.93 EIC Christos S. Mantzoros, MD, PhD, DSc.

The 21st WCIRDC will feature a robust Poster Hall, Oral Abstract Presentations, an attractive Exhibit Hall, and Industry Supported non-CME programs featuring important new scientific concepts with some of the world's best-known educators.

I look forward to you attending this exciting conference on December 7–9, 2023, at Hilton Universal City Los Angeles, California. We hope to see you there.

Best regards,



Best regards,

[Signature]
Yehuda Handelsman, MD
Chair & Program Director

Scientific Organizing Committee - International Committee for Insulin Resistance - ICIR

Yehuda Handelsman, MD Chair
Tarzana, CA

Richard N. Bergman, PhD
Los Angeles, CA

Zachary T. Bloomgarden, MD
New York, NY

Matthew J. Budoff, MD
Los Angeles, CA

Sonia Caprio, MD
New Haven, CT

Robert J. Chilton, DO
San Antonio, TX

Kenneth Cusi, MD
Gainesville, FL

Jaime A. Davidson, MD
Dallas, TX

Ralph A. DeFronzo, MD
San Antonio, TX

Vivian A. Fonseca, MD
New Orleans, LA

W. Timothy Garvey, MD
Birmingham, AL

Peter J. Grant, MD
Leeds, United Kingdom

Jennifer B. Green, MD
Durham, North Carolina

George Grunberger, MD
Bloomfield Hills, MI

Chris K. Guerin, MD
Oceanside, CA

Ania M. Jastreboff, MD, PhD
New Haven, Connecticut

Paul S. Jellinger, MD
Hollywood, FL

Samuel Klein, MD
St. Louis, MO

Mikhail N. Kosiborod, MD
Kansas City, MO

Ronald M. Krauss, MD
Berkeley, CA

Norman E. Lepor, MD
Los Angeles, CA

Derek LeRoith, MD, PhD
New York, NY

Philip Levy, MD
Phoenix, AZ

Ildiko Lingvay, MD, MPH, MSCS
Dallas, Texas

Christos S. Mantzoros, MD, PhD
Harvard, MA

Nikolaus Marx, MD
Aachen, Germany

Tracey L. McLaughlin, MD
Stanford, CA

Christian W. Mende, MD
La Jolla, CA

Erin D. Michos, MD, MHS
Baltimore, Maryland

Jorge Plutzky, MD
Boston, MA

Richard E. Pratley, MD
Orlando, FL

Arun J. Sanyal, MD
Richmond, VA

Philipp E. Scherer, PhD
Dallas, TX

Alan R. Sinaiko, MD
Minneapolis, MN

Bart Staels, PhD
Lille, France

Pam R. Taub, MD
San Diego, CA

Muthiah Vaduganathan, MD, MPH
Boston, MA

Matthew R. Weir, MD
Baltimore, MD

Paul Zimmet, AO, PhD
Melbourne, Australia



PROGRAM DESCRIPTION

The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 21st year, stands as a distinctive and vibrant multidisciplinary CME conference. Serving as the paramount global assembly dedicated to diabetes, obesity, lipids, cardiovascular-kidney, and liver diseases.

The Congress intricately weaves together basic research and clinical practice in pursuit of our guiding theme: Exploring New Frontiers in Metabolism — Tomorrow's Clinical Science Today.

Participants are able to earn up to 26.75 CME & ABIM-MOC credits.

The WCIRDC program features a unique convergence of basic and clinical science. For over two decades, it has convened physicians, clinicians, researchers, and other healthcare professionals into an international arena, crafting an exclusive program that seamlessly bridges the latest advancements from

bench-to-bedside-to-bench. Often resonating with the words, "I heard it first at the WCIRDC," the program provides an unparalleled opportunity for attendees to directly engage with distinguished global faculty, within an intimate setting, propelling explorations into the most current understanding of metabolic diseases and the unfolding emerging therapeutic approaches.

Since the seminal work of Dr. Gerald Reaven, crystallizing the interplay of insulin resistance, diabetes, obesity, and cardiovascular disease, the congress's scope has expanded. It now encompasses domains such as the kidney, liver, brain, bone, cancer, and beyond. The congress agenda includes dyslipidemia, atherosclerosis, hypertension, hypercoagulation, and inflammation. It also underscores the intricate interplay between Diabetes-Cardio-Renal and Metabolic Diseases. The program will cover updates on pharmaceutical interventions, including incretins- GLP1 ra and dual agonists, SGLT2i & SGLT2/1i, PCSK9 i, MRA, bempedoic acid and IPE, will be illuminated. The aim is to foster an in-depth

understanding of state-of-the-art pathophysiology, novel medical interventions, and the development of comprehensive clinical management strategies.

To bridge the gap between research and clinical practice, live Q&A and panel discussions will follow each session, exploring their implications in clinical scenarios. Enhanced interaction with faculty and fellow attendees will be facilitated through extended breaks and social events.

The Congress garners cutting-edge abstracts from both emerging researchers and renowned leaders across the globe. The best abstracts will be presented orally. There will be a key note presentation by professor Paul Zimmet, the recipient of the Gerald Reaven Distinguished Leader Award. Clinical workshops and meet the experts sessions allow for small groups learning and intimate face to face interaction with some of the best known leaders.

PROGRAM OBJECTIVES

The program is designed to evaluate both clinical and basic science aspects of diabetes, obesity, CVD and CKD, focusing on insulin resistance, incretins, the gut, the brain, the kidney and the heart. The goal is to understand pathophysiology and to develop appropriate comprehensive clinical management plans.

Upon completion of this meeting, participants should be able to:

- Discuss the effects of insulin resistance on the heart, kidney, and liver
- Describe the relationship between diabetes, obesity, kidney disease, and heart disease
- Implement best practices for the prevention and management of CKD, HF, and CVD
- Describe the recommended uses of SGLT2 inhibitors for the treatment of HF
- Describe the contemporary role of SGLT2 inhibitors in CKD with and without diabetes as consistent with approved indications
- Describe the benefits of GLP1-RAs in patients with ASCVD or at risk of ASCVD events
- Evaluate the evidence supporting the use of new and emerging therapies to reduce cardiovascular mortality in patients with cardiometabolic disease
- Explain the roles of diabetes and insulin resistance in the development of CKD, HF, and CVD
- Evaluate the impact on clinical practice of new CVOTs in patients with diabetes and other cardiometabolic diseases
- Design therapeutic regimens for patients with multiple cardiorenal and metabolic disorders that capitalize on agents with broad effects across the spectrum of these comorbidities
- Utilize technology to enhance the effectiveness of therapeutics

TARGET AUDIENCE

This educational initiative is designed for endocrinologists, cardiologists, nephrologists, family physicians, internists, diabetologists, gastroenterologists, pediatricians, OB/GYNs, researchers, nurse practitioners, physician assistants, dietitians, diabetes educators, and other healthcare professionals interested in the pathophysiology, prevention, and treatment of diabetes, obesity, CVD, CKD, HF, and associated conditions, as well as the effect of these conditions on health and society.

6:45 am	Pre-Registration		
7:00 am – 8:00 am	EXHIBIT HALL OPENS Coffee will be served		
7:00 am – 7:45 am	Breakfast Session BMF-219: An Oral Menin Inhibitor in Clinical Development as a Short-term Therapy to Address the Root Cause of Diabetes, Beta-cell Dysfunction Supported by Biomea Fusion	Non-CME Education	Product Theater Hall
	Priyanka Somanath, PhD 	Thomas Butler, MS, MBA 	Rohit Kulkarni, MD, PhD 
			Juan Frias, MD 
8:00 am – 8:15 am	Welcome & Introduction Pre-CME Questions		Yehuda Handelsman, MD
Session 1	Endothelium and Cardiometabolic Disorders		
8:15 am – 9:30 am	Chairs: Vivian A. Fonseca, MD • Derek LeRoith, MD, PhD		
8:15 am	The Effects of RYGB on Cholesterol and Bile Acid Metabolism in Humans		Bart Staels, PhD
8:35 am	Endothelial-Mesenchymal Transition in Cardiovascular Disease (EndMT)		Jorge Plutzky, MD
8:55 am	The Role of SGLTx in ACS, A. Fib & Metabolism- A Translational Approach		Robert J. Chilton, DO
9:15 am – 9:30 am	Panel Discussion and Q&A		
Session 2	ASCVD Epidemiology, Pathophysiology & Management		
9:30 am – 10:45 am	Chairs: Ronald M. Krauss, MD • Robert J. Chilton, MD		
9:30 am	Importance of Cardiovascular Risk Assessment and Multiple Risk Factor Control in Diabetes		Nathan D. Wong, PhD
9:50 am	Common Molecular Mechanisms Drive Cardiometabolic and Vascular Diseases Outcomes- Clinical Implications		W. Timothy Garvey, MD
10:10 am	The Relationships Between HDL Dysfunction, Genetic Very Small LDL, CAC and Insulin Resistance		Arthur S. Agatston, MD
10:30 am – 10:45 am	Panel Discussion and Q&A		
10:45 am – 11:15 am	REFRESHMENT BREAK at the Exhibit Hall		
Session 3	Lipidology Toward 2024 - Panel Session		
11:15 am – 12:10 pm	Chairs: Erin D. Michos, MD, MHS • Chris K. Guerin, MD		
11:15 am	The Role of the Mitochondrial/ER Axis in Cholesterol Metabolism and Statin Myopathy Lp(a), CETP / BA-CLEAR / Very High HDL Discussions and Q&A		Ronald M. Krauss, MD
			Seth S. Martin, MD, MHS
			Arthur S. Agatston, MD
12:10 pm			
Session 4	Concurrent Sessions: Meet the Experts		
12:15 pm – 1:00 pm	Ralph A. DeFronzo, MD Vivian A. Fonseca, MD Jennifer B. Green, MD Yehuda Handelsman, MD	Insulin Resistance – Intensive Management of DM DCRM Risk Prediction CKD Emerging Strategies Technology in DM and CRM	Sierra C/D (Lecture Hall) Club Hiro Salon 6AB
1:00 pm – 2:00 pm	LUNCH BREAK		
1:10 pm – 1:55 pm	Lunch Session Jardiance® (empagliflozin) tablets: A Peer Review of the Latest Clinical Data and Dosing Recommendations Supported by Boehringer Ingelheim–Lilly	Non-CME	Product Theater Hall Christian Mende, MD 

THURSDAY, DECEMBER 7 (Cont.)

Session 5

Metabolic Science

2:00 pm – 2:50 pm

Chairs: Richard N. Bergman, PhD • Phillip E. Scherer, PhD

2:00 pm

Genome- Proteome- Phenome & Mendelian Randomization Studies, Elucidating Novel Pathways and Treatments- Clinical Implication in Cardiometabolic Disorders

Christos S. Mantzoros, MD, PhD

2:20 pm

The Role of mRNA Modifications in the Regulation of Metabolism

Rohit Kulkarni, MD, PhD

2:40 pm – 2:50 pm

Panel Discussion and Q&A

Session 6

The Future of HTN

2:50 pm – 3:40 pm

Chairs: Pam R. Taub, MD • Chris W. Mende, MD

2:50 pm

Refractory HTN and New Drugs & Procedures in the Future

Norman E. Lepor, MD

3:10 pm

Need for New Agents to Overcome Healthcare Disparity in Hypertension

Keith C. Ferdinand, MD

3:30 pm – 3:40 pm

Panel Discussion and Q&A

Session 7

DCRM 2.0 – Update and Global Transformation

3:40 pm – 4:10 pm

Chairs: Richard E. Pratley, MD • Matthew R. Weir, MD

3:40 pm

DCRM 2.0 - Diabetes CardioRenal & Metabolic Diseases- Update & Global

Yehuda Handelsman, MD

3:55 pm – 4:10 pm

Panel Discussion and Q&A

4:10 pm – 4:40 pm

REFRESHMENT BREAK at the Exhibit Hall

Session 8

Insulin Resistance, Diabetes, and Beyond

5:00 pm – 6:35 pm

Chairs: Jennifer B. Green, MD • Jorge Plutzky, MD

4:40 pm

Brain HDL and Alzheimer's Disease: Toward Therapeutic Applications

Hussein Yassine, MD

5:00 pm

Pulmonary Disease in Diabetes- Another Final Frontier?

Peter J. Grant, MD

5:20 pm

Contemporary Nomenclature of Fatty Liver Disease Impact on Diagnosis and Management

Rohit Loomba, MD, MHS

5:40 pm

Vascular Aging in CKD

Matthew R. Weir, MD

6:00pm

Management of Diabetes in Patients with Cancer Addressing Impact of Cancer Therapy

Emily J. Gallagher, MD, PhD

Overcoming Treatment Challenges: Management of Patients with Diabetes and Cancer

6:20 pm – 6:35 pm

Panel Discussion and Q&A

6:35pm – 7:30 pm WELCOME & POSTER RECEPTION AT EXHIBIT HALL

7:30 pm – 9:15 pm

Dinner CME Symposium

Supported by **AstraZeneca**

Winning The Trifecta of Diabetes, Heart and Kidney Diseases

Chairs: Yehuda Handelsman, MD • Muthiah Vaduganathan, MD, MPH

7:30 pm Introduction & Pre-CME Questions

7:50 pm Early Intervention in Diabetes Addressing Pathophysiology in Preventing Comorbidities

Muthiah Vaduganathan, MD, MPH

8:10 pm SGLT2i Effects Across The Spectrum of CKD And Multiple Populations

Vivian A. Fonseca, MD

8:30 pm Impact of SGLT2i on HF Outcomes in Various Populations & The Range of LVEF

Peter Rossing, MD

8:50 pm **Panel Discussion and Q&A:** Changing the Trajectory of Heart Failure and CKD,

Muthiah Vaduganathan, MD, MPH

Implementing Guidelines Directed Medical Therapy

Panel: Vivian A. Fonseca, MD • Christian W. Mende, MD • Erin D. Michos, MD, MHS

Peter Rossing, MD • Muthiah Vaduganathan, MD, MPH

Moderator: Yehuda Handelsman, MD

9:10 pm Concluding Remarks & Post-CME Questions

9:15 pm Adjourn



FRIDAY, DECEMBER 8

7:00 am	Registration		
7:00 am – 8:00 am	EXHIBIT HALL OPENS		
7:00 am – 7:45 am	Breakfast Session	Non-CME	Product Theater Hall
	The Dual Dilemma: Navigating Cardiorenal Risk in CKD Associated with T2D Supported by Bayer		Dharmesh S. Patel, MD, MBBS 
8:00 am – 8:15 am	Summary of Day 1 and Pre-CME Questions		Zachary T. Bloomgarden, MD
Session 9	Women's Health		
8:15 am – 9:05 am	Chairs: Ania M. Jastreboff, MD • Pam R. Taub, MD		
8:15 am	Infertility, Assisted Reproductive Technology, and Cardiovascular Risk		Erin D. Michos, MD, MHS
8:35 am	Sex Differences in Cardiovascular Risk Associated with Pre, Newly Diagnosed, and Undiagnosed- Diabetes		Vivian A. Fonseca, MD
8:55 am – 9:05 am	Panel Discussion and Q&A		
Session 10	The Multiple Faces of Insulin Resistance		
9:05 am – 10:20 am	Chairs: Ralph A. DeFronzo, MD • Peter J. Grant, MD		
9:05 am	Insulin Resistance in T2DM: Whole Body, Organ, Cellular, and Molecular Pathogenesis		Ralph A. DeFronzo, MD
9:25 am	Insulin Resistance and Myocardial Energy Metabolism: Implications for Therapy		E. Dale Abel, MD, PhD
9:45 am	Which Comes First: Insulin Resistance or Obesity?		Samuel Klein, MD
10:05 am – 10:20 am	Panel Discussion and Q&A		
10:20 am – 10:50 am	REFRESHMENT BREAK at the Exhibit Hall		
Session 11	Progress in Pediatric Obesity and T2D: New and Advanced Treatments		
10:50 am – 12:05 pm	Chairs: Sonia Caprio, MD • Alan R. Sinaiko, MD		
10:50 am	GLP-1 RA for the Treatment of Youth Onset Obesity and T2D: From Fantasy to Reality		Silva Arslanian, MD
11:10 am	Achieving Metabolic Homeostasis in Youth with Obesity, Prediabetes/T2D and NAFLD, using Semaglutide 2, 4 mg.		Sonia Caprio, MD
11:30 am	Novel Treatments on the Horizon for Youth with Obesity, Fatty Liver & T2D		Rohit Kohli, MBBS, MS
11:50 am – 12:05 pm	Panel Discussion and Q&A		
12:05 pm – 1:05 pm	LUNCH BREAK		
12:15 pm – 1:00 pm	Lunch Session	Non-CME	Product Theater Hall
	Mounjaro® (tirzepatide) Product Theater Supported by Lilly		Steven Edelman, MD 
Session 12	Joint Session with Metabolism		
1:05 pm – 2:20 pm	Chairs: Christos S. Mantzoros, MD, PhD • Tracey L. McLaughlin, MD, MS		
1:05 pm	Vascular Mineralocorticoid Receptors, Vascular Insulin Sensitivity in Cardiometabolic Disorders: From Physiology to Clinical Relevance		Michael A. Hill, PhD
1:25 pm	Metabolic Surgery Important Role in the Comprehensive Management of Metabolic Diseases		Geltrude Mingrone, MD, PhD
1:45 pm	Cardiorenal Protection with SGLT2 Inhibitors: From Physiology to Clinical Outcomes to the Future in Heart Failure and Diabetic Kidney Disease		David Cherney, MDCM, PhD
2:05 pm – 2:20 pm	Panel Discussion and Q&A		

FRIDAY, DECEMBER 8 (Cont.)

Session 13

Non-CME: A Glimpse into The Future - What's in the Pipeline?

2:20 pm – 3:20 pm

Chairs: Ralph A. DeFronzo, MD • Christos S. Mantzoros, MD, PhD

2:20 pm

Regeneron

2:35 pm

Esperion

2:50 pm

Corcept

3:05 pm – 3:20 pm

Panel Discussion and Q&A

3:20 pm – 4:35 pm

REFRESHMENT BREAK at the Exhibit Hall

Boaz Hirshberg, MD
Stephen L. Pinkosky, PhD
Joseph K. Belanoff, MD

3:40 pm – 4:25 pm

Reception Session

Non-CME Education

Product Theater Hall

The Evolving Cardiovascular-Renal-Metabolic Paradigm: How Can Healthcare Systems Better Match Science?
Supported by **Boehringer Ingelheim**

*Refreshments will be served

Pamela Kushner, MD



David Cherney, MD



Yehuda Handelsman, MD



Session 14

Contemporary Management of Diabetes

4:35 pm – 6:15 pm

Chairs: George Grunberger, MD • Paul S. Jellinger, MD

4:35 pm

Molecular Mechanisms by Which Glucagon Regulates Hepatic Mitochondrial Oxidation and Gluconeogenesis – Implications for Dual and Triple GLP-1 Analogs

4:55 pm

Incretins in Diabetes- The New, the Newest and the Future

5:15 pm

Application of CGM to Diabetes Prevention

5:35 pm

Overcoming Clinical Inertia: The COORDINATE- Diabetes Example

5:55 pm – 6:15 pm

Panel Discussion and Q&A

Gerald I. Shulman, MD, PhD
Richard E. Pratley, MD
Tracey L. McLaughlin, MD, MS
Jennifer B. Green, MD

6:15 pm – 7:30 pm

Dinner CME Symposium

Supported by **Lexicon Pharmaceuticals**



Breaking New Ground in Heart Failure Treatment

Chairs: Matthew J. Budoff, MD • Yehuda Handelsman, MD

6:15 pm Introduction & Pre CME Questions

6:25 pm Prevalence, Pathophysiology and Morbidities of Heart Failure

6:40 pm Contemporary Approach to Management of Heart Failure

6:55 pm Sotagliflozin: The Next Generation of Heart Failure Management

7:10 pm **Panel Discussion, Q&A, and Post-CME:** Advancing the Care of Heart Failure- Relationship to CKD

Panel: Matthew J. Budoff, MD • Stephen J. Greene, MD • Darren McGuire, MD, MHSc • Matthew R. Weir, MD

Moderator: Yehuda Handelsman, MD

7:25 pm Post-CME Questions & Concluding Remarks

7:30 pm Adjourn

Yehuda Handelsman, MD
Matthew J. Budoff, MD
Stephen J. Greene, MD
Darren McGuire, MD, MHSc

7:30pm - 9:00 pm

Abstract Oral Presentation

Cheese and Wine

Chair: Zachary T., Bloomgarden, MD

Abstract Committee: Ralph A. DeFronzo, MD • Vivian A. Fonseca, MD • George Grunberger, MD

Derek LeRoith, MD • Philip Levy, MD • Christian W. Mende, MD • Richard E. Pratley, MD • Matthew R. Weir, MD

Abstracts are published in **Metabolism** - Editor-in-Chief: **Christos S. Mantzoros, MD, PhD**



SATURDAY, DECEMBER 9, 2023

7:00 am Registration

7:00 am – 7:45 am

Breakfast Session

Non-CME Education

Product Theater Hall

Evolving Perspectives in Hyperglycemia Secondary to Hypercortisolism
Supported by **Corcept**

Ralph A. DeFronzo



Yehuda Handelsman, MD



8:00 am – 8:05 am Oral Abstract Winner Award Presentation

Zachary T. Bloomgarden, MD

8:05 am – 8:20 am

Summary of Day 2 and Pre-CME Questions

Zachary T. Bloomgarden, MD

Session 15

Cardiomyopathy & Heart Failure - Panel Session

8:20 am – 10:00 am

Chairs: Nikolaus Marx, MD • Mikhail N. Kosiborod, MD

8:20 am

Contemporary Approach to Cardiac Amyloidosis
Cardiomyopathy and Pregnancy
The Role of Diuretics in Heart Failure
Management of Heart Failure: Bridging the Gap Between Evidence and Practice
Discussions and Q&A

Michelle M. Kittleson, MD, PhD
Uri Elkayam, MD
Stephen J. Greene, MD
Gregg C. Fonarow, MD

10:00 am

10:00 am – 10:10 am

REFRESHMENT BREAK

Session 16

CVOT & Guidelines

10:10 am – 11:00 am

Chairs: Peter J. Grant, MD • Matthew R. Weir, MD

10:10 am

CVOTs Update

Mikhail N. Kosiborod, MD

10:30 am

2023 ESC Diabetes and Cardiovascular Disease Guidelines

Nikolaus Marx, MD

10:50 am – 11:00 am

Panel Discussion and Q&A

Session 17

Gerald Reaven Distinguished Leader in Insulin Resistance 2023 Award

11:00 am

Award Presentation by Peter J. Grant, MD • Samuel Klein, MD

11:05 am

Insulin Resistance and its outcomes in T2DM: A Historical and Epidemiological Perspective

Paul Zimmet, AO, MD, PhD

11:35 am – 11:45 am

Q&A



11:45 am – 12:45 pm

LUNCH & CHECK-OUT BREAK

11:55 am – 12:40 pm

Lunch Session

Non-CME

Product Theater Hall

Innovation and Improved Outcomes with Abbott Diabetes Care
Supported by **Abbott**

George Grunberger, MD



Session 18

Fat Mass and Adipocyte

12:45 pm – 1:35 pm

Chairs: Richard E. Pratley, MD • Bart Staels, PhD

12:45 pm

The Role of Relative Fat Mass- RFM vs. BMI Predicting T2D, Heart Failure and CVD

Richard N. Bergman, PhD

1:05 pm

GIP-R Action in the Adipocyte

Philipp E. Scherer, PhD

1:25 pm – 1:35 pm

Panel Discussion and Q&A

SATURDAY, DECEMBER 9 (Cont.)

Session 19	Contemporary Approach to Obesity - Panel Session	
1:35 pm – 2:55 pm	Chairs: Samuel Klein, MD • W. Timothy Garvey, MD	
1:35 pm	Nutrient-Stimulated Hormone-Based Therapies for Obesity Treatment: Clinical Application and Pipeline Diets, Calorie Restrictions vs Intermittent Fasting Addressing The Energy Balance Model Weight and Weight Changes Impact on CV Risk Discussions and Q&A: Does The Availability of Effective Pharmacotherapy To Treat Obesity Negates The Need For The Other Treatment Options?	Ania M. Jastreboff, MD, PhD Eric Ravussin, PhD Neha J. Pagidipati, MD, MPH
2:55 pm		
2:55 pm – 3:10 pm	REFRESHMENT BREAK	
Session 20	Not All Diabetes – is Type 2 DM	
3:10 pm – 4:00 pm	Chairs: Paul Zimmet, MD • Zachary T. Bloomgarden, MD	
3:10 pm	Diabetes Secondary to Pancreatitis	Mark O. Goodarzi, MD, PhD
3:30 pm	2023 Prevention and Management of T1D- The New Reality	George Grunberger, MD
3:50 pm – 4:00 pm	Panel Discussion and Q&A	
Session 21	ASCVD Imaging - Panel Session	
4:00 pm – 5:00 pm	Chairs: Matthew J. Budoff, MD • Norman E. Lepor, MD	
4:00 pm	Imaging in Predicting Subacute Atherosclerosis CTA in Predicting Survival- the CONFIRM Registry Association of Coronary Artery Calcium & Spine Bone Density Comparing Plaques in Patients with & without Statins +/- DM Discussions and Q&A	Matthew J. Budoff, MD • Michael J. Blaha, MD, MPH
5:00 pm		
Session 22	Concurrent Sessions: Clinical Workshop	Wine and Cheese
5:00 pm – 6:00 pm	Lipids Diabetes HTN/CKD	Paul S. Jellinger, MD & Paul D. Rosenblit, MD, PhD George Grunberger, MD Christian W. Mende, MD Sierra C/D (Lecture Hall) Club Hiro
6:00 pm	Adjourn	

21ST WCIRDC PROGRAM COMMITTEE

Yehuda Handelsman, MD, Chair • Matthew Budoff, MD • Zachary Bloomgarden, MD, MACE • Sonia Caprio, MD
Robert Chilton, DO • Ralph DeFronzo, MD • Vivian Fonseca, MD • Tim Garvey, MD • Peter Grant, MD • Jennifer Green, MD
George Grunberger, MD • Chris Guerin, MD • Paul Jellinger, MD • Mikhail Kosiborod, MD
Ronald Krauss, MD • Norman Lepor, MD • Nikolaus Marx, MD • Tracy McLaughlin, MD, MS • Derek Leroith, MD, PhD
Christos Mantzoros, MD, PhD • Chris Mende, MD • Erin Michos, MD, MHS • Jorge Plutzky, MD • Richard Pratley, MD • Arun Sanyal, MD, MBBS
Phil Scherer, PhD • Alan Sinaiko, MD • Bart Staels, PhD • Pam Taub, MD • Matthew Weir, MD • Paul Zimmet, MD, AO, PhD • Renee Asp, BS

FACULTY 2023



Yehuda Handelsman, MD, MACE, FACP, FNLA FASPC, FAHA

Medical Director & Principal Investigator
The Metabolic Institute of America
Chair Scientific Advisory board, DCMi- Diabetes
CardioRenal & Metabolism Institute
Chair & Program Director, HiD-Heart in Diabetes &
WCIRDC- World Congress on IR, DM & CVD
Tarzana, California



E. Dale Abel, MD, PhD

Endocrinologist and Chair
Department of Medicine
David Geffen School of Medicine at UCLA
Executive Medical Director
UCLA Health System's Department of Medicine
Los Angeles, California



Arthur S. Agatston, MD, FACC

Chairman and CEO
The Agatston Center for Preventive Medicine
Clinical Professor of Medicine
FIU Herbert Wertheim College of Medicine
Clinical Associate Professor of Medicine,
University of Miami Miller School of Medicine
Medical Director of Wellness and Prevention
Baptist Health South Florida
Miami Beach, Florida



Silva Arslanian, MD

Richard L. Day Professor of Pediatrics
Pediatric Endocrinology
Metabolism & Diabetes Mellitus
University of Pittsburgh School of Medicine
Director, Pediatric Clinical & Translational
Research Center
Scientific Director, Center for Pediatric Research
in Obesity & Metabolism
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania



Richard N. Bergman, PhD

Alfred Jay Firestein Chair in Diabetes Research
Professor, Department of Biomedical Sciences
Cedars-Sinai
Director, Sports Spectacular Diabetes and Obesity
Wellness and Research Center
Professor-in-Residence, Department of Medicine, UCLA
Los Angeles, California



Michael Joseph Blaha, MD, MPH

Professor of Cardiology and Epidemiology, Johns Hopkins
University School of Medicine
Director of Clinical Research, Johns Hopkins Ciccarone
Center for the Prevention of Cardiovascular Disease
Associate Editor, the Journal of Cardiovascular Computed
Tomography
Baltimore, Maryland



Zachary T. Bloomgarden, MD, MACE

Clinical Professor, Department of Medicine
Icahn School of Medicine at Mount Sinai
Editor, The Journal of Diabetes
New York, New York



Matthew J. Budoff, MD, FACC, FAHA

Professor of Medicine
David Geffen School of Medicine at UCLA
Endowed Chair of Preventive Cardiology
Lundquist Institute
Program Director of Cardiac CT
Division of Cardiology Harbor-UCLA Medical Center
Torrance, California



Sonia Caprio, MD

Professor of Pediatric Endocrinology
Yale University School of Medicine
New Haven, Connecticut



David Cherney, MD CM, PhD, FRCP(C)

Professor of Medicine, University of Toronto
Clinician Scientist, Division of Nephrology
University Health Network
Director, Renal Physiology Laboratory
University Health Network
Senior Scientist, Toronto General Hospital
Research Institute
Toronto, Ontario



Robert J. Chilton, DO, FACP, FACC FAHA, MACOI, FASCAI

Professor of Medicine, Division of Cardiology
Associate Program Director, Interventional Cardiology
The University of Texas Health Science Center
San Antonio, Texas



Ralph A. DeFronzo, MD

Professor of Medicine
Chief, Diabetes Division
The University of Texas Health Science Center
Deputy Director, Texas Diabetes Institute
San Antonio, Texas



Uri Elkayam, MD

Professor of Medicine (Cardiology)
Obstetrics and Gynecology
Director of the Maternal Cardiology Program
Los Angeles, California



Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA

Gerald S. Berenson Chair in Preventative Cardiology
Professor of Medicine,
Tulane University School of Medicine
New Orleans, Louisiana



Gregg C. Fonarow, MD, FACC, FAHA, FHFSa

Eliot Corday Professor of
Cardiovascular Medicine and Science
Director, Ahmanson-UCLA Cardiomyopathy Center
Co-Director, UCLA Preventative Cardiology Program
Los Angeles, California



Vivian A. Fonseca, MD, FRCP

Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Medical Center
New Orleans, Louisiana



Emily J. Gallagher, MD, PhD

Associate Professor, Division of Endocrinology
Diabetes and Bone Disease
Associate Program Director, Internal Medicine Residency
Program Director
Research Track for the Internal Medicine Residency
Program Principal Investigator
Endocrine Fellows Foundation, Fellows Development
New York City, New York



W. Timothy Garvey, MD

Butterworth Professor of Nutritional Sciences
Chair, Department of Nutrition Sciences
School of Health
Director, UAB Diabetes Research Center
Professions Senior Scientist
UAB Nutrition Obesity Research Center
Geriatric Research Education and Clinical Centers
Investigator and Staff Physician
Birmingham VA Medical Center
University of Alabama
Birmingham, Alabama



Mark O. Goodarzi, MD, PhD, FACP

Eris M. Field Chair, Diabetes Research
Director, Endocrine Genetics Laboratory
Director, Division of Endocrinology, Diabetes & Metabolism
Professor of Medicine, Biomedical Sciences
Cedars-Sinai Medical Center, Associate Professor
David Geffen School of Medicine at UCLA
Los Angeles, California



Peter J. Grant, MD, FRCP, FMedSci

Professor of Medicine and Diabetologist
Honorary Consultant Physician
Leeds Teaching Hospitals NHS Trust
Division of Cardiovascular & Diabetes Research
University of Leeds
Leeds, United Kingdom



FACULTY 2023



Jennifer B. Green, MD
Professor of Medicine, Division of Endocrinology
Duke University Medical Center
Duke Clinical Research Institute
Durham, North Carolina



Stephen J. Greene, MD
Assistant Professor of Medicine (Cardiology)
Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina



George Grunberger, MD, FACP, MACE
Chairman, Grunberger Diabetes Institute
Clinical Professor
Internal Medicine and Molecular Medicine & Genetics
Wayne State University School of Medicine
Professor, Internal Medicine
Oakland University William Beaumont
School of Medicine
Bloomfield Hills, Michigan



Chris K. Guerin, MD, FACE, FNLA
Medical Director, Diabetes Education Services and the
Diabetes Service Line
Past Chief, Division of Internal Medicine and Chair
Department of Medicine
Tri-City Medical Center
Founder, Advanced Metabolic Care and Research
San Diego, California



Michael A. Hill, PhD
Interim Director
Dalton Cardiovascular Research Center
Professor, Department of Medical Pharmacology
and Physiology
MU School of Medicine
The University of Missouri School of Medicine
Columbia, Missouri



Ania M. Jastreboff, MD, PhD
Associate Professor of Medicine
Endocrinology & Pediatrics
Yale University School of Medicine
Director, Yale Obesity Research Center (Y-Weight)
Co-Director, Yale Center for Weight Management
Board of Directors,
American Board of Obesity Medicine
New Haven, Connecticut



Paul S. Jellinger, MD, MACE
Professor of Clinical Medicine
Voluntary Faculty, University of Miami
Miller School of Medicine
The Center for Diabetes & Endocrine Care
Hollywood, Florida



Michelle M. Kittleston, MD, PhD
Professor of Medicine (Cardiology)
Smidt Heart Institute
Cedars-Sinai Medical Center
Beverly Hills, California



Samuel Klein, MD
Director, Center for Human Nutrition
Chief Scientific Officer
Sansum Diabetes Research Institute
Washington University School of Medicine
Saint Louis, Missouri



Rohit Kohli, MBBS, MS
Professor of Pediatrics, Keck School of Medicine of USC
Chief, Division of Gastroenterology
Hepatology and Nutrition
Director, The George Donnell Society
for Pediatric Scientists
Los Angeles, California



Mikhail N. Kosiborod MD, FACC, FAHA
Professor of Medicine, Saint Luke's
Mid-America Heart Institute
University of Missouri
Kansas City School of Medicine
Kansas City, Missouri



Ronald M. Krauss, MD
Senior Scientist and Director, Atherosclerosis Research
Children's Hospital Oakland Research Institute
Adjunct Professor, Department of Medicine, UCSF
Adjunct Professor, Department of Nutritional Sciences
University of California, Berkeley
Berkeley, California



Rohit Kulkarni, MD, PhD
Margaret A. Congleton Chair and Co-Head
Islet & Regenerative Biology, Joslin Diabetes Center
Professor of Medicine, Harvard Medical School
Principle Faculty, Harvard Stem Cell Institute
Boston, Massachusetts



Norman E. Lepor, MD, FACC, FAHA, FSCAI
Clinical Professor of Medicine
David Geffen School of Medicine at UCLA
Attending Cardiologist, Cedars-Sinai Heart Institute
Co-director, Cardiovascular Imaging
Westside Medical Imaging
Director of Clinical Research
Westside Medical Associates
Los Angeles, California



Derek LeRoith, MD, PhD, FACP
Professor of Medicine, Director of Research
Division of Endocrinology, Diabetes & Bone Disease
Department of Medicine
Icahn School of Medicine at Mt. Sinai
New York, New York



Rohit Loomba, MD, MHS
Professor of Medicine
Chief, Division of Gastroenterology and Hepatology
Director, NAFLD Research Center
UC San Diego School of Medicine
University of California at San Diego
UC San Diego Health
San Diego, California



Christos S. Mantzoros, MD, DSc, PhD h.c. mult.
Professor of Medicine, Harvard Medical School and
Boston University School of Medicine
Chief of Endocrinology, Diabetes, and Metabolism
Boston VA Healthcare System
Director of Human Nutrition
Beth Israel Deaconess Medical Center
Editor-in-Chief, Metabolism, Clinical & Experimental
Harvard, Massachusetts



Seth S. Martin, MD, MHS, FACC, FAHA, FASPC
Professor of Medicine (Cardiology)
Johns Hopkins Hospital
Johns Hopkins University School of Medicine
Baltimore, Maryland



Nikolaus Marx, MD, FESC, FAHA
Director of Medical Clinic I - Cardiology, Angiology
and Internal Intensive Care Medicine
University Hospital RWTH Aachen
Professor of Medicine - Cardiology
Internal Medicine and General Medicine
RWTH Aachen University
Aachen, Germany



Darren McGuire, MD, MHS
Professor of Internal Medicine
Division of Cardiology
Dallas Heart Ball Chair
for Research on Heart Disease in Women
UT Southwestern Medical Center
Deputy Editor, Circulation
Dallas, Texas



Tracey L. McLaughlin, MD, MS
Professor of Medicine, Division of Endocrinology
Clinician Investigator
Stanford University School of Medicine
Stanford, California



Christian W. Mende, MD, FACP, FASN, FASH
Clinical Professor of Medicine
University of California San Diego
La Jolla, California

FACULTY 2023



Erin D. Michos, MD, MHS
FAHA, FACC, FASE, FASPC

Director of Women Cardiovascular Health Research
Associate Director of Preventive Cardiology
Division of Cardiology
Johns Hopkins University School of Medicine
Director, IMPACT Center at JHU
Co-Editor in Chief
American Journal of Preventive Cardiology
Baltimore, Maryland



Geltrude Mingrone, MD, PhD

Associate Professor of Internal Medicine
Catholic University, School of Medicine
Chief, Division of Obesity and Related Disorders
Policlinico A. Gemelli Hospital
Professor of Diabetes and Nutrition
King's College London, UK
Rome, Italy



Neha J. Pagidipati, MD, MPH

Associate Professor, Division of Cardiology
Duke University School of Medicine
Director, Duke Cardiometabolic Prevention Clinic
Duke Clinical Research Institute
Durham, North Carolina



Jorge Plutzky, MD

Director, The Vascular Disease Prevention Program
Director, Preventive Cardiology,
Brigham and Women's Hospital
Associate Professor, Harvard Medical School
Boston, Massachusetts



Richard E. Pratley, MD

Samuel E. Crockett Chair in Diabetes Research
Medical Director, AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins University School of Medicine
Orlando, Florida



Eric Ravussin, PhD

Director, Nutrition Obesity Research Center
Douglas L. Gordon Chair in Diabetes and Metabolism
Boyd Professor and Associate Executive Director
for Clinical Science
Metabolic Chambers Human Translational Physiology
Pennington Biomedical Research Center
Louisiana State University
Baton Rouge, Louisiana



Paul D. Rosenblit, MD, PhD, FACE, FNLA

Clinical Professor, Medicine
Division of Endocrinology, Diabetes, Metabolism
University of California, Irvine School of Medicine
Director, & Site Principal Investigator
Diabetes / Lipid Management & Research Center
Huntington Beach, California



Peter Rossing, MD, DMSc

Professor Department of Clinical Medicine
University of Copenhagen
Steno Diabetes Center Copenhagen
Herlev, Denmark



Philipp E. Scherer, PhD

Professor, Department of Internal Medicine
Gifford O. Touchstone Jr. and Randolph G. Touchstone
Distinguished Chair in Diabetes Research
Director, Touchstone Diabetes Center
The University of Texas, Southwestern Medical Center
Dallas, Texas



Gerald I. Shulman, MD, PhD

George R. Cowgill Professor of Medicine (Endocrinology)
Professor of Medicine
and Cellular & Molecular Physiology
Co-Director Yale Diabetes Research Center
Yale University School of Medicine
New Haven, Connecticut



Alan R. Sinaiko, MD

Professor Emeritus, Department of Pediatrics
Division of Pediatric Nephrology
University of Minnesota Medical School
Pediatrics and Division of Epidemiology
School of Public Health
Minneapolis, Minnesota



Bart Staels, PhD

Co-founder of GENFIT
Chairman of the Scientific Advisory Board
Full Professor, Faculty of Pharmacy, University de Lille
Director, Inserm UMR1011, Institut Pasteur de Lille
Lille, France



Pam R. Taub, MD, FACC, FASPC

Director of Step Family Foundation Cardiovascular
Rehabilitation and Wellness Center
Professor of Medicine
Division of Cardiovascular Medicine
UC San Diego Health System
La Jolla, California



Muthiah Vaduganathan, MD, MPH FACC FHFA

Cardiologist and Clinical Trialist
Brigham and Women's Hospital and
Harvard Medical School
Co-director, Center for
Cardiometabolic Implementation Science
Boston, Massachusetts



Matthew R. Weir, MD

Professor and Chief Division of Nephrology
Department of Medicine
University of Maryland
School of Medicine
Baltimore, Maryland



Nathan D. Wong, PhD, MPH, FACC
FAHA, FNLA, FASPC

Cardiovascular Epidemiologist
Specialist in Preventive Cardiology
Professor and Director
Heart Disease Prevention Program
Division of Cardiology, University of California, Irvine
Adjunct Professor of Epidemiology, UCLA and UC Irvine
Public Health & Radiology, UC Irvine
Irvine, California



Hussein Yassine, MD

Kenneth and Bette Volk Endowed
Professor of Neurology
Associate Professor, Department of Medicine
Keck School of Medicine of
the University of Southern California
Los Angeles General Medical Center
Los Angeles, California



Paul Zimmet, AO, MD, PhD, FRACP, FRCP, FTSE

Professor of Diabetes, Monash University
Honorary President, International Diabetes Federation
2018 Victoria Senior Australian of the Year
Co-Director, The Sagol Center for Epigenetics of
Metabolism and Ageing, Tel Aviv Medical Center, Israel
Doctor of Laws, Honoris Causa (Monash)
Doctor Philosophiae Honoris Causa (Tel Aviv)
Honoris Causa Doctoris
(Complutense University (Madrid)
Doctor of the University, Honoris Causa (Adelaide)
Doctor of Philosophy, Umea University (Sweden)
Melbourne, Australia



(Pipeline Speaker)
Boaz Hirshberg, MD

Senior Vice President, Clinical Sciences
General Medicine, Regeneron
Tarrytown, New York



(Pipeline Speaker)
Stephen Pinkosky, PhD

Vice President, Head of Discovery and Early
Development, Esperion
Ann Arbor, Michigan



(Pipeline Speaker)
Joseph K. Belanoff, MD

Chief Executive Officer, President and Director
Co-founder, Corcept Therapeutics
Redwood, California



REGISTRATION INFORMATION

www.wcir.org/registration

Email info@tmioa.com To register by phone (818) 342-1889

All 21st WCIRDC participants must be vaccinated in order to attend the live in person meeting. For further information please contact info@tmioa.com

CME Accreditation:

For CME questions related to WCIRDC, please contact our CME Coordinator Renee Asp at renee@aspencmehelp.com

This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Designation Statement:

PESI Inc. has designated this Live activity for a maximum of 26.75 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

MOC Points with ABIM:

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn MOC points of Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Total qualifying MOC points 26.75

International CME:

International Physicians are formally eligible for AMA PRA Category 1 Credit[™].

Physician Assistants:

AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit[™] for the PRA from organizations accredited by ACCME.

Nurses:

For the purpose of re-certification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit[™] issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

Pharmacists

For the purpose of re-certification, the American Council of Pharmacy Education accepts AMA PRA Category 1 Credit[™] issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

CDE

The National Certification Board for Diabetes Educators recognizes courses sponsored by PESI Inc. as approved ACCME provider. Total qualifying continuing education hours 26.75

Registered Dietitians

For the purpose of re-certification, the Commission on Dietetic Registration recognizes courses accredited with AMA PRA Category 1 Credit[™].

Satisfactory Completion for Credits

All attendees must have completed and submitted an online course attendance/evaluation immediately following onsite attendance. Each session claimed for credit must be attended in its entirety. Attendees will be able to print a certificate of attendance following the submission of online evaluation. Physician certificates of credit will be emailed two to three weeks after the CME activity.

*** For Physicians to have credits recorded to ACCME PARs for licensing and certification board records, physicians must provide:**

1) State of licensure, 2) license ID #, 3) Birthdate - month and day, and 4) ABIM #.

Enduring/ On-Demand CME Activity

This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Designation Statement

PESI Inc. has designated this Enduring activity for a maximum of 26.75 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Available online at www.wcir.org from December 10, 2023 through March 10, 2024.



2023 PARTNERS

ASSOCIATED ORGANIZATIONS

Premier Associated Organizations

- Clinical Association of California Endocrinologists (CACE)
- California Chapter American College of Cardiology (CAACC)
- American Society for Preventive Cardiology (ASPC)

Associated Organizations

- American Society of Endocrine Physician Assistants (ASEPA)
- American Society of Preventive Oncology (ASPO)
- Association of Diabetes Care and Education Specialists (ADCES)
- Endocrine Nurses Society (ENS)
- International Federation for Surgery of Obesity & Metabolic Disorders (IFSO)
- Israel Endocrine Society (IES)
- Point of Care Network (POCN)
- Society for Endocrinology (SFE)
- Societa Italiana Endocrinologia (SIE)
- World Obesity Federation (WOF)
- National Kidney Foundation of America (NKFA)
- Korean Heart Rhythm Society (KHRS)

MEDIA PARTNERS

Premier Media Partners

- Metabolism (Elsevier)
- Healio Cardiology Today & Endocrine Today
- Closed Concerns
- American Journal of Cardiology (Elsevier)
- American Journal of Managed Care (MJH Life Sciences)
- HCPLive Network (MJH Life Sciences)

Media Partners

- CN1699 Media
- ConferenceLocate.com
- Connected Health
- Diabetes and Vascular Research (Sage)
- Diabetes in Control
- Elsevier
- Endocrine Web
- Endocrinology Network
- Family Heart Foundation
- Frontiers in Clinical Diabetes and Healthcare
- Journal of Diabetes
- Metabolism and Target Organ Damage
- MDPI
- MedTech
- MEDTube
- Nutrients Open Access Journal
- OAE Publishing Inc.
- PharmaVoice
- Physician's Weekly
- Practical Cardiology
- Society for Vascular Surgery
- Strategic AJMC Alliance (MJH Life Sciences)
- Strategic Endocrinology Network Alliance (MJH Life Sciences)
- Strategic Practical Cardiology Alliance (MJH Life Sciences)
- The Journal of Cardiovascular Aging
- The Journal of Cardiovascular Development and Disease
- The Journal of Clinical Medicine
- VenueDir
- VP Vessel Plus

**THE INTERNATIONAL COMMITTEE FOR
INSULIN RESISTANCE GRATEFULLY ACKNOWLEDGES**

EDUCATIONAL GRANT

ASTRAZENECA
LEXICON PHARMACEUTICALS
BAYER
BOEHRINGER INGELHEIM-LILLY
AMGEN
ESPERION THERAPEUTICS

CORPORATE SUPPORT
EMERALD LEVEL



Abbott



Boehringer
Ingelheim *Lilly*



Boehringer
Ingelheim



Lilly



The 8th Annual Heart in Diabetes
Where the heart, kidney, and diabetes meet in clinical practice.

SAVE-THE-DATE
June 7 -9, 2024

Hilton Philadelphia at Penn's Landing
201 S. Christopher Columbus Blvd. Philadelphia, PA 19106

JOIN US FOR ANOTHER GROUNDBREAKING CME CONFERENCE.



heartindiabetes.com

SAVE THE DATE | December 12-14, 2024

22nd
WCIRDC

World Congress Insulin Resistance
DIABETES & CARDIOVASCULAR DISEASE



Exploring New Frontiers in Metabolism - Tomorrow's Clinical Science Today

SEE YOU NEXT YEAR!

Hilton Universal

555 Universal Hollywood Dr, Universal City, CA 91608



wcir.org



@wcirdc



SUPPORT • REGISTRATION • ACCOMMODATIONS • EXHIBITION

818.342.1889 | 818.342.1538 | info@tmioa.com

www.wcir.org

Metabolic Endocrine Education Foundation (MEEF)
638 Lindero Canyon Dr Suite #380 Oak Park, CA 91377